Skip to main
VALN

Valneva SE (VALN) Stock Forecast & Price Target

Valneva SE (VALN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Valneva SE has demonstrated a positive outlook due to the increased confidence in the commercial uptake of its Lyme vaccine candidate, VLA15, particularly as assumptions for Europe align more closely with those in the US. The company reported strong immune responses following a third yearly booster for the VLA15 vaccine, suggesting promising efficacy that may enhance future market potential. Despite a recent suspension of the Ixchiq vaccine by the FDA, overall earnings have met expectations, indicating stability as Valneva continues to focus on its robust pipeline and commitment to developing life-saving vaccines.

Bears say

Valneva SE faces significant risks including potential clinical and regulatory setbacks, which could adversely impact product sales and market competitiveness. Specific safety concerns related to its vaccine IXCHIQ have diminished its competitive edge against alternatives, such as Bavarian Nordic's chikungunya vaccine, despite claims of superior long-term protection. Furthermore, the removal of projected U.S. sales for IXCHIQ and expectations for limited uptake in Europe due to these concerns and emerging competition contribute to a negative outlook on the company's stock performance.

Valneva SE (VALN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Valneva SE (VALN) Forecast

Analysts have given Valneva SE (VALN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Valneva SE (VALN) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Valneva SE (VALN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.